The Zacks Analyst Blog Highlights: REGN, SNY, GILD And MRNA

For Immediate Release

Chicago, IL – March 18, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ,Sanofi (PA:SASY) (NASDAQ:SNY) , Gilead (NASDAQ:GILD) and Moderna (NASDAQ:MRNA) .

Here are highlights from Tuesday’s Analyst Blog:

Regeneron/Sanofi to Test Drug on Severe Coronavirus

Regeneron Pharmaceuticals, Inc. and Sanofi announced a program to study their rheumatoid arthritis (RA) drug, Kevzara, to treat patients hospitalized with severe infection due to the coronavirus disease, COVID-19.

A U.S. based phase II/III study has been initiated at medical centers in New York. It will begin enrolling patients immediately. The study, which will enroll up to 400 patients, will test the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo. While Regeneron will lead the U.S. studies, Sanofi will take care of the ex-U.S. studies, which will be initiated in the coming weeks.

Kevzara is an anti-interleukin (IL)-6 receptor monoclonal antibody. In patients who are severely or critically ill with COVID-19, the IL-6 pathway may play an important role in driving the overactive inflammatory response in the lungs, per the press release. The press release mentioned that in a Chinese study, it was observed that another IL-6 receptor antibody (tocilizumab) led to rapidly reduced fevers in critically ill COVID-19 patients.

Also, 75% of patients reduced their need for supplemental oxygen within days of being treated with the medicine. So Regeneron and Sanofi believe that Kevzara due to its IL-6 receptor inhibition may emerge as a treatment option for critically-ill COVID-19 patients,

Kevzara is presently marketed jointly by Sanofi and Regeneron for the treatment of moderately-to-severely active rheumatoid arthritis (RA) in adult patients who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX). It is being evaluated in phase III studies for giant cell arteritis and polymyalgia rheumatica and in phase II studies in pediatric populations for two indications - polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic

Regeneron’s shares are up 17.4% this year so far against the industry’s decline of 11.8%.

Sanofi’s shares have underperformed the industry this year so far. The stock has declined 17.3% in the said time frame compared with the industry’s decrease of 11%.

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19. In addition to the Kevzara studies, Regeneron has an agreement with the U.S. Department of Health and Human Services (HHS) for manufacturing antibodies targeting SARS-CoV-2, the virus that causes COVID-19. Gilead’s investigational antiviral candidate, remdesivir, is being evaluated in phase III studies to treat COVID-19.

Sanofi has joined forces with BARDA of the U.S. Department of Health and Human Services to quickly develop a vaccine for COVID-19. Sanofi will advance the development of a COVID-19 vaccine by leveraging work on a pre-clinical vaccine candidate for SARS (severe acute respiratory syndrome). COVID-19 and SARS are both coronaviruses that can cause respiratory diseases. Other big drugmakers, J&J (NYSE:JNJ) and GlaxoSmithKline have also expressed interest in developing a vaccine for COVID-19.

CEPI has provided funding of around $24 million to biotechs like Moderna, Novavax CureVac and Inovio to have potential vaccine candidates in early-stage clinical studies within a few months. In fact, on Monday, Moderna announced that the first participant has been dosed in a phase I study of its mRNA vaccine candidate for COVID-19

While Regeneron has a Zacks Rank #1 (Strong Buy), Sanofi has a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank stocks here.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Join us on Facebook (NASDAQ:FB): http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.